Language：English   Publisher：(公社)日本医学放射線学会  

局所進行子宮頸癌(LACC)に対し、経直腸超音波(TRUS)ガイド下経腟的アプローチによる組織内照射併用腔内照射(IC/IS BT)を行い、有効性と安全性を後向きに調査した。外照射療法とTRUSガイド下で経腟アプローチによりIC/IS BTの治療を受けたLACC患者30例(年齢31～82歳)を調査対象とし、2年局所制御率(LC)、無増悪生存率(PFS)および全生存率(OS)をKaplan-Meier法で分析した。また、遅発性有害事象に基づきIC/IS BTの安全性についても評価した。その結果、経過観察期間の中央値は22ヵ月で、2年LC、PFSおよびOSはそれぞれ90%、61%、82%であった。また、IC/IS BT法に関連した重篤な合併症例はみられず、グレード3以上の遅発性有害事象としては、グレード4の結腸穿孔が認められた。以上より、経腟的アプローチによるTRUSガイド下でのIC/IS BTは、LACCにおいて、安全且つ良好な局所腫瘍制御が得られることが確認された。

Language：English   Publisher：Anticancer Research  

Background/Aim: Radiomics, which links radiological image features with patient prognoses, is expected to be applied for the prediction of the clinical outcomes of radiotherapy. We investigated the clinical and radiomic factors associated with recurrence patterns after stereotactic body radiotherapy (SBRT) for non-small cell lung cancer (NSCLC). Patients and Methods: We retrospectively analyzed 125 patients with histologically confirmed NSCLC who underwent SBRT between April 2003 and June 2017 at our institution. A radiomic score was calculated from five radiomics features (histogram and texture features) selected using the LASSO Cox regression model. These features were extracted from the gross tumor volume (GTV) in three-dimensional wavelet decomposition CT images. We used univariate and multivariate analyses to determine the associations between local control (LC) time and metastasis-free survival (MFS), clinical factors (age, sex, performance status, operability, smoking, histology, and tumor diameter), and the radiomic score. Results: With a median follow-up of 37 months, the following 3-year rates were observed: overall survival, 80.9%; progression-free survival, 61.7%; LC, 75.1%, and MFS; 74.5%. In multivariate analysis, histology (squamous cell carcinoma vs. non-squamous cell carcinoma, p=0.0045), tumor diameter (>3 cm vs. ≤3 cm, p=0.039); and radiomic score (>0.043 vs. ≤0.043, p=0.042) were significantly associated with LC, and the radiomic score (>0.304 vs. ≤0.304, p<0.001) was significantly associated with MFS. Conclusion: Histology, tumor diameter, and radiomic score could be significant factors for predicting NSCLC recurrence patterns after SBRT.

DOI： 10.21873/anticanres.16699

Web of Science

Scopus

PubMed

Language：English   Publisher：BMC Cancer  

Background: Rhabdomyosarcoma is the most common soft tissue sarcoma in children, but rare in adults. Para-meningeal rhabdomyosarcoma in head and neck (PM-HNRMS) is less applicable for surgery due to the anatomic reason. PM-HNRMS has a poor prognosis in children. However, its clinical outcomes remain unclear in adults due to the rarity. Further, there is almost no detailed data about salvage therapy. Methods: We retrospectively examined the adult patients with PM-HNRMS treated at institutions belonging to the Kyushu Medical Oncology Group from 2009 to 2022. We evaluated the overall survival (OS) and progression-free survival (PFS) of the patients who received a first-line therapy. We also reviewed the clinical outcomes of patients who progressed against a first-line therapy and received salvage therapy. Results: Total 11 patients of PM-HNRMS received a first-line therapy. The characteristics were as follows: median age: 38 years (range 25 – 63 years), histology (alveolar/spindle): 10/1, and risk group (intermediate/high): 7/4. As a first-line therapy, VAC and ARST0431-based regimen was performed in 10 and 1 patients, respectively. During a first-line therapy, definitive radiation for all lesions were performed in seven patients. The median PFS was 14.2 months (95%CI: 6.0 – 25.8 months): 17.1 months (95%CI: 6.0 – not reached (NR)) for patients with stage I-III and 8.5 months (95%CI: 5.2 – 25.8 months) for patients with stage IV. The 1-year and 3-year PFS rates were 54.5% and 11.3% for all patients. Median OS in all patients was 40.8 months (95%CI: 12.1 months–NR): 40.8 months (95%CI: 12.1 – NR) for patients with stage I-III and NR for patients with stage IV. The 5-year OS rate was 48.5% for all patients. Among seven patients who received salvage therapy, three are still alive, two of whom remain disease-free for over 4 years after completion of the last therapy. Those two patients received multi-modal therapy including local therapy for all detected lesions. Conclusion: The cure rate of adult PM-HNRMS is low in spite of a first-line therapy in this study. Salvage therapy might prolong the survival in patients who received the multi-modal therapy including local therapy for all detected lesions.

DOI： 10.1186/s12885-023-11528-4

Web of Science

Scopus

PubMed

Publisher：金原出版  

DOI： 10.18888/rp.0000002176

CiNii Research

Language：Japanese   Publisher：金原出版(株)  

70歳代男性。胸部中部食道癌に対する化学放射線療法から7ヵ月後、縦隔リンパ節再発が認められた。FP療法を1コース施行するも効果なく、重粒子線治療を施行したところ、奏効した。最終治療から5年以上経過現在、再発や重篤な有害事象はみられない。

Event date： 2015.10

Language：English  

Venue：Henry B. Gonzalez Convention Center, San Antonio   Country：United States  

Language：Japanese  

Language：Japanese  

Language：Japanese  

Language：Japanese